P-PSMA-101

N/A

Report date: 2025/02/19 20:00:46

Base Information

Drug NameP-PSMA-101

Drug Alias NameP-PSMA-101

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity

TargetsProstate-specific antigen

Therapy Area/IndicationsProstatic DiseasesProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[9]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPoseida Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPoseida Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsProstatic DiseasesProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[9]

Other Information

ATC CodeN/A